Title A prospective phase 2 study to assess minimal residual disease ixazomib, lenalidomide, dexamethasone (IRD) treatment for newly diagnosed transplant eligible multiple myeloma patients /
Authors Silvennoinen, Raija ; Partanen, Anu ; Waage, Anders ; Pečeliūnas, Valdas ; Schjesvold, Fredrik ; Anttila, Pekka ; Uttervall, Katarina ; Säily, Marjaana ; Putkonen, Mervi ; Carlson, Kristina ; Haukas, Einar ; Sankelo, Marja ; Szatkowski, Damian ; Hansson, Markus ; Marttila, Anu ; Axelsson, Per ; Svensson, Ronald ; Lauri, Birgitta ; Mikkola, Maija ; Karlsson, Conny ; Abelsson, Johanna ; Ahlstrand, Erik ; Sikiö, Anu ; Klimkowska, Monika ; Matuzevičienė, Rėda ; Hoyseter Fenstad, Mona ; Ilveskero, Sorella ; Nahi, Hareth
DOI 10.1097/01.HS9.0000970496.55340.69
Full Text Download
Is Part of HemaSphere: 28th Congress of the European Hematology Association EHA2023, June 8 - 15, Frankfurt, 2023 : abstract book.. Philadelphia : Wolters Kluwer Health, Inc.. 2023, vol. 7, suppl. S3, poster no. P898, p. 1693-1694.. eISSN 2572-9241
Keywords [eng] Multiple myeloma ; Minimal residual disease (MRD) ; High risk
Published Philadelphia : Wolters Kluwer Health, Inc
Type Conference paper
Language English
Publication date 2023
CC license CC license description